No Data
No Data
Innovent Bio (01801.HK) received JPMorgan's shareholding of 10.1839 million shares.
According to the latest equity disclosure data from the Hong Kong Stock Exchange on October 15, 2024, innovent bio (01801.HK) received a shareholding of 10.1839 million shares at an average price of HK$48.0257 per share from JPMorgan Chase & Co. on October 8, 2024, involving approximately HK$0.489 billion. After the shareholding, JPMorgan Chase & Co.'s latest holding of good warehouses is 102,360,912 shares, and the proportion of good warehouses held has increased from 5.65% to 6.25%.
Hong Kong Stocks Fall on Uncertainty in Further Stimulus; Pharma Firms Lead Decline
[Brokerage Focus] Tianfeng maintains a 'buy' rating on Innovent Bio (01801), indicating that its research and development pipeline will enter a period of product harvesting.
Kin Wus financial news | tianfeng securities issued a research report, in the first half of 2024, innovent bio (01801) total revenue was 3.95 billion yuan, a year-on-year increase of 46.3%; product revenue was 3.81 billion yuan, a year-on-year increase of 55.1%. The company's product has seen high-speed growth year-on-year for several consecutive quarters. From the fourth quarter of 2023 to the second quarter of 2024, the product revenue increased by over 65%, over 60%, and about 50% compared to the same period. At the same time, the company's sales scale effect is evident, with a decrease in multiple expense rates. In the first half of 2024, the gross margin was 84.1%, up 1.8 percentage points, and the sales and marketing expense ratio was 48.6%, down 5.9.
Hong Kong stocks anomaly | Innovent Bio (01801) fell another 10% during the day, reaching a strategic cooperation with Beijing Aosaikang Pharmaceutical, the founder recently reduced holdings by over 0.15 billion Hong Kong dollars of stocks
Innovent Bio (01801) fell by another 10% during the day, as of the time of publication, a decrease of 4.92%, closing at HKD 47.35, with a turnover of 1.627 billion Hong Kong dollars.
Express News | Innovent Biologics Inc - Obtains Exclusive Commercialization Rights for Limertinib in Mainland China
Express News | Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-Generation Egfr Tki for the Treatment of Lung Cancer
No Data
No Data